QF
GNMX

QVT Financial’s Aevi Genomic Medicine Inc GNMX Stock Holding History

QVT Financial’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-123,500
Closed -$688K – 90
2016
Q3 		$688K Sell
123,500
-725,300
-85% -$4.14M 0.03% 70
2016
Q2 		$4.56M Sell
848,800
-18,808
-2% -$98.8K 0.31% 57
2016
Q1 		$3.82M Hold
867,608
– – 0.23% 71
2015
Q4 		$5.22M Buy
867,608
+600,000
+224% +$4.07M 0.29% 60
2015
Q3 		$2.09M Buy
+267,608
New +$2.07M 0.07% 82

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

QVT Financial's GNMX Position: Q4 2016 in Review

QVT Financial sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2016, closing a stake of 123,500 shares — an estimated $688K sold.

QVT Financial first reported a position in GNMX in Q3 2015 and held it in 5 quarters. The position peaked at $5.22M in Q4 2015. 76 funds tracked by Wall St. Rank hold GNMX as of Q4 2016.

  • QVT Financial reported no remaining Aevi Genomic Medicine Inc position as of Q4 2016 after selling out during the quarter.
  • QVT Financial sold 123,500 Aevi Genomic Medicine Inc shares in Q4 2016, an estimated $688K.
  • QVT Financial first reported a position in Aevi Genomic Medicine Inc in Q3 2015 and held it in 5 quarters.
  • QVT Financial's Aevi Genomic Medicine Inc position peaked at $5.22M in Q4 2015.
  • 76 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2016.

Based on QVT Financial's 13F filing for Q4 2016, filed 14 Feb 2017.